C4 Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de C4 Therapeutics es Andrew Hirsch , nombrado en Sep 2020, tiene una permanencia de 4.17 años. compensación anual total es $3.79M, compuesta por 16.9% salario y 83.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.081% de las acciones de la empresa, por valor de $250.81K. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 7.3 años, respectivamente.
Información clave
Andrew Hirsch
Chief Executive Officer (CEO)
US$3.8m
Compensación total
| Porcentaje del salario del CEO | 16.9% |
| Permanencia del CEO | 4.2yrs |
| Participación del CEO | 0.08% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 7.3yrs |
Actualizaciones recientes de la dirección
Recent updates
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk
Nov 15
C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate
Oct 02Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher
Aug 09C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up
Aug 03Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$4m | US$639k | -US$132m |
| Sep 30 2023 | n/a | n/a | -US$135m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$131m |
| Dec 31 2022 | US$3m | US$614k | -US$128m |
| Sep 30 2022 | n/a | n/a | -US$107m |
| Jun 30 2022 | n/a | n/a | -US$99m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$952k | US$580k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$80m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$21m | US$168k | -US$66m |
Compensación vs. Mercado: La compensación total de Andrew($USD3.79M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.16M).
Compensación vs. Ingresos: La compensación de Andrew ha aumentado mientras la empresa no es rentable.
CEO
Andrew Hirsch (53 yo)
4.2yrs
Permanencia
US$3,790,099
Compensación
Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$3.79m | 0.081% $ 250.8k | |
| Co-Founder | no data | US$111.41k | 0.45% $ 1.4m | |
| Chief Medical Officer | 1.3yrs | US$1.96m | 0.013% $ 40.0k | |
| Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| CFO & Treasurer | 1.2yrs | sin datos | 0.025% $ 77.7k | |
| Chief Accounting Officer | 1.2yrs | sin datos | 0.0021% $ 6.6k | |
| Chief Scientific Officer | less than a year | sin datos | sin datos | |
| Senior Manager of Investor Relations | no data | sin datos | sin datos | |
| Chief Legal Officer & Corporate Secretary | 4.3yrs | US$3.38m | 0.020% $ 62.1k | |
| Chief People Officer | 3.8yrs | sin datos | 0.020% $ 62.1k | |
| Senior Vice President of Strategic Alliances & Business Development | 8.7yrs | sin datos | sin datos | |
| Senior Vice President of Chemistry | 3.8yrs | sin datos | sin datos |
3.8yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CCCC se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 4.1yrs | US$3.79m | 0.081% $ 250.8k | |
| Co-Founder | 8.9yrs | US$111.41k | 0.45% $ 1.4m | |
| Co-Founder & Member of Scientific Advisory Board | 8yrs | sin datos | sin datos | |
| Lead Independent Director | 8.9yrs | US$157.91k | 0.69% $ 2.1m | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.3yrs | sin datos | sin datos | |
| Independent Chairman | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 7.3yrs | sin datos | sin datos | |
| Independent Director | 2.7yrs | US$126.41k | 0.0080% $ 24.8k | |
| Member of Clinical Advisory Board | no data | sin datos | sin datos |
7.3yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de CCCC se considera experimentada (7.3 años de antigüedad promedio).